Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 01, 2016 10:05 ET | Source: Vaccinex, Inc.

Vaccinex Receives FDA Fast Track Designation for VX15 Antibody for the Treatment of Huntington’s Disease

ROCHESTER, N.Y., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Vaccinex, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VX15 as a potential...
October 20, 2015 13:17 ET | Source: Vaccinex, Inc.

Vaccinex Announces Publication of Results From a Phase I Trial of Anti-Semaphorin 4D Antibody, VX15/2503, in Patients With Advanced Solid Tumors

ROCHESTER, N.Y., Oct. 20, 2015 (GLOBE NEWSWIRE) -- Vaccinex Inc., a clinical-stage biotechnology company engaged in the discovery and development of therapeutic monoclonal antibodies to treat cancer...
June 24, 2015 13:17 ET | Source: Vaccinex, Inc.

Vaccinex, Inc. Announces the Initiation of a Phase 2 Clinical Trial of Its Investigational VX15/2503 Antibody in Huntington's Disease (the SIGNAL Trial)

ROCHESTER, N.Y., June 24, 2015 (GLOBE NEWSWIRE) -- Vaccinex, Inc. announced today that it has initiated a Phase 2 clinical trial to assess the safety, tolerability and efficacy of anti-semaphorin 4D...
March 31, 2015 13:17 ET | Source: Vaccinex, Inc.

Vaccinex Provides an Update on Its VX15/2503 Phase 1 Clinical Trial in Multiple Sclerosis Patients

ROCHESTER, N.Y., March 31, 2015 (GLOBE NEWSWIRE) -- Vaccinex, Inc. today announced the successful completion of a multicenter phase 1, randomized, double-blind, placebo-controlled, single...
March 19, 2015 13:30 ET | Source: Vaccinex, Inc.

Vaccinex Signs Multi-Target Antibody Discovery Deal With Five Prime Therapeutics

ROCHESTER, N.Y., March 19, 2015 (GLOBE NEWSWIRE) -- Vaccinex, Inc. announced today that the company has entered into a multi-target collaboration agreement with Five Prime Therapeutics, Inc. to...
February 17, 2015 11:05 ET | Source: Vaccinex, Inc.

Vaccinex Announces the Publication of Data Demonstrating Preclinical Efficacy in an Animal Model of Huntington Disease

ROCHESTER, N.Y., Feb. 17, 2015 (GLOBE NEWSWIRE) -- Vaccinex, Inc., a clinical-stage immunotherapy company engaged in the discovery and development of therapeutic monoclonal antibodies, today announced...